De Klerk J M, Zonnenberg B A, Huiskes A W, Han S H, Blijham G H, Van Rijk P P
Afd. Nucleaire Geneeskunde, Academisch Ziekenhuis, Utrecht.
Ned Tijdschr Geneeskd. 1998 Nov 28;142(48):2618-22.
The skeleton is a common site for metastases in patients with prostate and breast cancer. Beside analgesic therapy and external beam radiotherapy, the use of bone-seeking radiopharmaceuticals gives pain relief. Analogues of these pharmaceuticals are also applied in skeletal scintigraphy. They accumulate at the site of high osteoblast activity and in this way they exert a local favourable influence on metastases through their radiation (beta particles or conversion electrons). The bone-seeking radiopharmaceuticals include strontium-89 chloride and rhenium-186 hydroxyethylidenediphosphonate. The main adverse reaction that has been observed is myelosuppression.
骨骼是前列腺癌和乳腺癌患者常见的转移部位。除了镇痛治疗和外照射放疗外，使用亲骨性放射性药物可缓解疼痛。这些药物的类似物也应用于骨闪烁显像。它们在成骨细胞活性高的部位聚集，通过其辐射（β粒子或转换电子）对转移灶产生局部有利影响。亲骨性放射性药物包括氯化锶-89和羟乙二膦酸铼-186。观察到的主要不良反应是骨髓抑制。
